Bavarian Nordic — Marts 2023
-
..står på side 23 og som vi allerede ved, "Financial implications in 2023 of the
travel vaccine portfolio acquisition
from Emergent BioSolutions
The acquired business is expected to add approximately DKK 200 million to revenue and a loss
of approximately DKK 400 million to EBITDA, not
included in the current company financial guidance
for 2023. " -
Financial implications in 2023 of the
travel vaccine portfolio acquisition
from Emergent BioSolutions
The acquired business is expected to add approximately DKK 200 million to revenue and a loss
of approximately DKK 400 million to EBITDA, not
included in the current company financial guidance
for 2023.
The expected loss is due to investments in the
Chikungunya Phase 3 program and inclusion of
necessary one-off integration costs. The financial
impact from the acquired business is pending final
cl -
Bavarian-finansdirektør venter opkøb på plads inden for tre måneder https://www.proinvestor.com/investornyt/948895/bavarian-finansdirektor-venter-opkob-pa-plads-inden-for-tre-maneder
-
Forsøget mod luftvejssygdommen RSV er dog stærkt afhængig af, at der er nok virussmitte til stede til, at man kan bruge de data, der er indsamlet. Det lader - til selskabets lettelse - indtil videre til at være tilfældet, fortæller Bavarian Nordics finansdirektør Henrik Juuel.
- Det har heldigvis vist sig at være en stærk RSV-sæson, og det kan vi forhåbentlig bekræfte med de data, vi kommer med. Det skal også gøre vores statistiske data mere solide, siger Henrik Juuel.
-
Pyha... lad os håbe på, at lille Bava kan tage kampen op mod de store drenge i forhold til R
SV! -
Den "uvildige" ekspertpanel anbefalede Pfizer med 7 mod 4 stemmer (RSV-vaccine)... det er ikke en overbevisende flertal, især når man så hører, at der var konstateret mulighed for nogle ret grimme bivirkninger
-
..den nye situationsrapport fra WHO om mpox, https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report---17---2-march-2023
-
..interessant omkring Afrika, "In the WHO African Region, one country is in the process of procuring vaccines for the response from the
manufacturer. Additionally, there have been on-going discussions with the European Commission/HERA, Japan,
South Korea, and United States to donate vaccines to the response and for further research in a range of settings." -
Tak for det @WT. “ In November 2022, a vaccine called OrthopoxVac was licensed in the Russian Federation for immunization against smallpox, mpox and other orthopoxviruses according to the rules for registration of medicines of the Eurasian Economic Union”…. Nå, ja, russerne må sikkert ikke købe Jynneos. Så mon ikke kineserne køber denne vaccine også
-
webcasten igang https://edge.media-server.com/mmc/p/4j48og9i
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind